共 25 条
Awake serial intralesional steroid injections without surgery as a novel targeted treatment for idiopathic subglottic stenosis
被引:69
|作者:
Franco, Ramon A., Jr.
[1
,2
]
Husain, Inna
[5
]
Reder, Lindsay
[6
]
Paddle, Paul
[3
,4
]
机构:
[1] Harvard Med Sch, Div Laryngol, Dept Otolaryngol, Boston, MA USA
[2] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA
[3] Monash Hlth, Clayton, Vic, Australia
[4] Alfred Hlth, Clayton, Vic, Australia
[5] Rush Univ, Dept Otolaryngol, Med Ctr, Chicago, IL 60612 USA
[6] Univ Southern Calif, Dept Otolaryngol, Los Angeles, CA USA
来源:
关键词:
Airway stenosis;
reconstruction;
idiopathic subglottic stenosis;
steroid injection;
in-office treatment;
LARYNGOTRACHEAL STENOSIS;
HYPERTROPHIC SCARS;
MANAGEMENT;
KELOIDS;
RESECTION;
D O I:
10.1002/lary.26874
中图分类号:
R-3 [医学研究方法];
R3 [基础医学];
学科分类号:
1001 ;
摘要:
Objectives/HypothesisThe fibrotic/erythematous appearance of the subglottis in idiopathic subglottic stenosis (iSGS) hints that it might respond to repeated intralesional steroid treatment similar to keloids. Study DesignRetrospective cohort study. MethodsThirteen iSGS subjects (six treated in-office with serial intralesional steroid injections [SILSI] versus seven treated endoscopically in the operating room [OR] followed by awake SILSI) between October 2011 and April 2017. Forced spirometry was performed before injections and at each follow-up visit (peak expiratory flow [%PEF] and peak inspiratory flow). Steroids were injected via transcricothyroid or transnasal routes. Injections were grouped into rounds of four to six injections separated by 3 to 5 weeks. ResultsThirteen subjects with a mean follow-up of 3 years (3.3 years for SILSI and 2.7 years for OR). Awake-only SILSI subjects had a mean improvement/round of 23.1% %PEF (range, 65.4%-88.6%), whereas the OR-treated subjects had a mean %PEF improvement/round of 25.1% (range, 57.4%-82.5%). Both groups had improved breathing, and the improvements were statistically equal (P=.569). SILSI subjects underwent 5.3 injections/round in 1.3 rounds, whereas OR subjects had 5.9 injections/round over 2.1 rounds. Statistically significant improvement was seen in %PEF for both groups (SILSI P=.007, OR P=.002). Overall, SILSI achieved sustained %PEF above 80% in 83% (5/6) and OR+SILSI 86% (6/7). ConclusionsSILSI in the awake outpatient setting can improve the airway caliber in iSGS and is equivalent to endoscopic OR treatment. We believe iSGS can be viewed as a chronic scarring/inflammatory condition that can benefit from steroid scar-modification therapy. Level of Evidence4. Laryngoscope, 128:610-617, 2018
引用
收藏
页码:610 / 617
页数:8
相关论文